FDA Clearance Tracker · K212778
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075)
Last checked: Nov 19, 2026Latest source record: Jul 15, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jul 15, 2022
Substantially Equivalent
Time to decision
317 days
Received Sep 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K212778
- Device name
- Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075)
- Applicant
- Abbott Molecular, Inc.
- Applicant location
- Des Plaines, IL
- Received
- Sep 1, 2021
- Decided
- Jul 15, 2022
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX)
- Device class
- Class II
- Regulation
- 21 CFR 866.3183
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QLX. The earliest in FDA's data is DEN200015, decided Jul 30, 2020.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K212778
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Abbott Molecular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
- Alinity m HR HPVPMA supplement
P230003-S006 · Decided Sep 10, 2025 · 264 days after receipt · Panel Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
K243489 · Decided Jul 28, 2025 · 258 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.